facebook button Cabozantinib plus Atezolizumab in Multiple Tumor Types
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Cabozantinib plus Atezolizumab in Multiple Tumor Types

Sponsor: Exelixis

Protocol XL184-021: A phase 1 trial of combination therapy comprised of cabozantinib and atezolizumab in patients with advanced or metastatic solid tumors. The trial is available to patients diagnosed with the following tumor types: Renal Cell Carcinoma Non-Small Cell Lung Cancer Castration-resistant Prostate Cancer Triple Negative Breast Cancer Ovarian Cancer Endometrial Cancer Hepatocellular Carcinoma Gastric Cancer Gastroesophageal Junction Adenocarcinoma Colorectal Cancer Head and Neck Cancer Differentiated Thyroid Cancer